Department of Clinical Pharmacology
Position: Doctor-in-training
ORCID: 0000-0002-9196-1936
T +43 1 40400-29810
valentin.aljalali@meduniwien.ac.at
Keywords
Antibiosis; Antiparasitic Agents; Clinical Trial, Phase I; Microdialysis; Pharmacokinetics; Positron-Emission Tomography
Research group(s)
- Section of Clinical Pharmacokinetics / Pharmacogenetics and Imaging
Head: Markus Zeitlinger
Research Area: Our main focus is the study of the drug distribution process by employing techniques to measure target site distribution directly, i.e. PET or microdialysis.
Members:
Research interests
My research focus lies on the investigation of the distribution of antimicrobial substances in the body (pharmacokinetics) in order to develop or optimize drug dosage regimens. Since sufficiently high drug levels at the site of action are essential for successful treatment, I explore in detail the pharmacokinetics at the target tissue. To this end, I frequently employ microdialysis studies.
As part of this research, I conduct studies in healthy volunteers as well as special patient populations.
Another focus of my work is the planning, execution and evaluation of early dose finding and safety studies - often as first-in-human (phase I) studies in the context of drug development.
Techniques, methods & infrastructure
- Plasma and tissue Microdialysis
- Ex-vivo Microdialysis
- PET imaging
- Non-compartmental analysis (NCA)
Selected publications
- al Jalali, V. et al. (2022) ‘Pilot Pharmacokinetic Study in Healthy Adults Using Intravascular Microdialysis Catheters Modified for Use in Paediatric Patients to Assess Vancomycin Blood Levels’, Clinical Pharmacokinetics, 62(1), pp. 77–87. Available at: http://dx.doi.org/10.1007/s40262-022-01190-7.
- al Jalali, V. et al. (2023) ‘Consecutive PSMA and AR PET imaging shows positive correlation to AR and PSMA protein expression in primary hormone naïve prostate cancer.’, Journal of Nuclear Medicine, p. jnumed.122.264981. Available at: http://dx.doi.org/10.2967/jnumed.122.264981.
- Al Jalali, V. et al. (2021) ‘Plasma and soft tissue pharmacokinetics of ceftolozane/tazobactam in healthy volunteers after single and multiple intravenous infusion: a microdialysis study’, Journal of Antimicrobial Chemotherapy, 76(9), pp. 2342–2351. Available at: http://dx.doi.org/10.1093/jac/dkab166.
- al Jalali, V. et al. (2020) ‘Clinical Pharmacokinetics of Fosfomycin after Continuous Infusion Compared with Intermittent Infusion: a Randomized Crossover Study in Healthy Volunteers’, Antimicrobial Agents and Chemotherapy, 65(1). Available at: http://dx.doi.org/10.1128/aac.01375-20.
- al Jalali, V. et al. (2019) ‘In vitro activity of voriconazole and amphotericin B against Candida albicans, Candida krusei, and Cryptococcus neoformans in human cerebrospinal fluid’, Infection, 47(4), pp. 565–570. Available at: http://dx.doi.org/10.1007/s15010-019-01275-9.